Beroni Group Limited
Beroni Group Limited
Your view on BNIGF
Overview
What the company does, where it operates, and who runs it.
About Beroni Group Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Boqing Zhang
- Headquarters
- Level 36, Gateway, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Boqing Zhang
- Headquarters
- Level 36, Gateway, Sydney, NSW, AU
Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifiers, water filters, and health care products and supplements in China, Australia, the United States, and Japan.
It operates through Nicobloc, Fogibloc Air Purifier, Olansi Water Filter, Health Supplements, Cosmetic products, and Viral Diagnostic Kits segments. The company's products include NicoBloc, a smoking cessation/harm reduction product; and Fogibloc, an air purifier system.
It also offers cosmetic products, such as V show rejuvenation liquids, hyaluronic acid moisturizing silk masks, and avocado poly-peptide intensive treatment silk masks.
In addition, the company provides SARS-CoV-2 IgG/IgM antibody detection kit, as well as sells CII-ArboViroPlex rRT-PCR assay, a diagnostic kit used to detect viruses such as Zika, Dengue, Chikungunya, and West Nile.
Further, it engages in the research and development of new drugs and clinical trial; gene detection and diagnosis, as well as sale of cell therapies for cancer and anti-aging treatments; developing new anti-cancer drugs; detection and diagnosis of infectious diseases; and e-commerce platform for pharmaceutical and healthcare products.
Additionally, the company sells stem cell cosmetic products. The company was founded in 2014 and is headquartered in Sydney, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Beroni Group Limited, and the rating behind it. BNIGF last traded at $0.0064; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Beroni Group Limited. Starting points for Beroni Group Limited: EPS -$0.12, beta 0.44 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Beroni Group Limited. Beroni Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Beroni Group Limited. Trailing twelve-month EPS for Beroni Group Limited stands at -$0.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Beroni Group Limited. Beroni Group Limited has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Beroni Group Limited valued side by side against its closest peers. Beroni Group Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Beroni Group Limited, and how their positions are changing. At a $220,063 market value, institutional positions materially move Beroni Group Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Beroni Group Limited executives and directors. Shares of Beroni Group Limited have traded between $0.0021 and $0.82 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Beroni Group Limited. Beroni Group Limited is a $220,063 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Beroni Group Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Beroni Group Limited. Coverage tracks Beroni Group Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.